Sandra Dai

1.4k total citations · 2 hit papers
11 papers, 747 citations indexed

About

Sandra Dai is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Sandra Dai has authored 11 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 3 papers in Hematology. Recurrent topics in Sandra Dai's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Sandra Dai is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). Sandra Dai collaborates with scholars based in United States, Italy and United Kingdom. Sandra Dai's co-authors include Carol Moreno, James P. Dean, Jan A. Burger, Thomas J. Kipps, Paul M. Barr, Peter Hillmen, Steven Coutré, Alessandra Tedeschi, David Simpson and Paolo Ghia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Sandra Dai

10 papers receiving 734 citations

Hit Papers

Long-term efficacy and safety of first-line ibrutinib tre... 2019 2026 2021 2023 2019 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. Leukemia profile →
  2. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    2019 307 citations Talha Munir, Jennifer R. Brown et al. American Journal of Hematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Dai United States 6 713 575 242 189 96 11 747
Emily Hsu United States 8 630 0.9× 527 0.9× 223 0.9× 179 0.9× 100 1.0× 29 705
Elizabeth Bilotti United States 12 584 0.8× 460 0.8× 206 0.9× 385 2.0× 58 0.6× 29 832
Ulrike Söling Germany 8 447 0.6× 380 0.7× 201 0.8× 126 0.7× 83 0.9× 16 525
Andrzej Pluta Poland 8 380 0.5× 295 0.5× 116 0.5× 186 1.0× 62 0.6× 23 519
Talha Munir United Kingdom 5 331 0.5× 264 0.5× 135 0.6× 97 0.5× 46 0.5× 16 365
Aileen Cohen United States 11 269 0.4× 244 0.4× 76 0.3× 125 0.7× 37 0.4× 30 366
Lucia Morello Italy 8 324 0.5× 316 0.5× 145 0.6× 77 0.4× 12 0.1× 15 443
Gerasimos Pangalis Greece 9 233 0.3× 184 0.3× 75 0.3× 108 0.6× 13 0.1× 21 376
George P. Keogh United States 6 177 0.2× 156 0.3× 68 0.3× 73 0.4× 68 0.7× 10 323
Zafiris Kartasis Greece 10 246 0.3× 164 0.3× 71 0.3× 488 2.6× 27 0.3× 16 676

Countries citing papers authored by Sandra Dai

Since Specialization
Citations

This map shows the geographic impact of Sandra Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Dai more than expected).

Fields of papers citing papers by Sandra Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Dai. The network helps show where Sandra Dai may publish in the future.

Co-authorship network of co-authors of Sandra Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Dai. A scholar is included among the top collaborators of Sandra Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Dai. Sandra Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
3.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2021). Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.. Journal of Clinical Oncology. 39(15_suppl). 7523–7523. 18 indexed citations
4.
5.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2019). Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 34(3). 787–798. 312 indexed citations breakdown →
6.
Munir, Talha, Jennifer R. Brown, Susan O’Brien, et al.. (2019). Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology. 94(12). 1353–1363. 307 indexed citations breakdown →
7.
Tedeschi, Alessandra, Jan A. Burger, Paul M. Barr, et al.. (2019). S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere. 3(S1). 5–6. 1 indexed citations
8.
Barr, Paul M., Alessandra Tedeschi, Peter Hillmen, et al.. (2019). Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood. 134(Supplement_1). 3054–3054. 2 indexed citations
9.
Barr, Paul M., Talha Munir, Jennifer R. Brown, et al.. (2019). Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. Journal of Clinical Oncology. 37(15_suppl). 7510–7510.
10.
Byrd, John C., Peter Hillmen, Susan O’Brien, et al.. (2017). Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. Journal of Clinical Oncology. 35(15_suppl). 7510–7510. 11 indexed citations
11.
Cao, Fenglin, et al.. (2015). Clinicopathological and phenotypic features of chronic NK cell lymphocytosis identified among patients with asymptomatic lymphocytosis. International Journal of Laboratory Hematology. 37(6). 783–790. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emily Hsu Breakdown of academic impact, for papers by Elizabeth Bilotti Breakdown of academic impact, for papers by Ulrike Söling Breakdown of academic impact, for papers by Andrzej Pluta Breakdown of academic impact, for papers by Talha Munir Breakdown of academic impact, for papers by Aileen Cohen Breakdown of academic impact, for papers by Lucia Morello Breakdown of academic impact, for papers by Gerasimos Pangalis Breakdown of academic impact, for papers by George P. Keogh Breakdown of academic impact, for papers by Zafiris Kartasis
Rankless by CCL
2026